Are you currently facing poor in vivo half-life, structural instability, and non-functional protein expression with small antibody fragments? Our Diabody Generation Service helps you obtain highly stable, high-affinity bispecific antibody fragments through advanced Fc-fusion and structural stabilization engineering. We deliver molecules with enhanced pharmacokinetic profiles ready for preclinical testing.
Contact our team to get an inquiry now!
Diabodies represent some of the most compact BsAbs. Their assembly involves fusing variable heavy chain (VH) and variable light chain (VL) domains via concise "GGGGS" peptide linkers. Nevertheless, this five-residue connector lacks sufficient length to bridge the approximate 35-angstrom gap between the C-terminal end of VH and the N-terminal end of VL. As a result, the two VH-linker-VL chains dimerize, creating a complex with dual antigen-binding regions, each composed of VH and VL segments originating from separate chains.
Fig.1 Diagram of tandem diabody procedure.
If the Fv domains within a diabody are homogeneous, the molecule is classified as monospecific. These diabodies promote homo-dimerization of target proteins since they can engage two identical protein molecules concurrently. Conversely, bispecific diabodies incorporate Fv regions sourced from two distinct antibodies, allowing them to connect disparate proteins and induce hetero-dimerization.
Following the advancement of Diabody, several modified BsAbs have been developed, such as scDiabody, Diabody-CH3, scDiabody-CH3, Diabody-Fc, and scDiabody-Fc. Within these variants, a disulfide bond may be added to enhance diabody stability, or a pliable linker is designed to join the two antibody chains.
Creative Biolabs stands as a partner in antibody fragment engineering, turning unstable constructs into clinical-grade assets. Our commitment to structural rigor and pharmacokinetic optimization ensures that your therapeutic pipeline is built on the most stable and functionally validated molecules available.
Experience the Creative Biolabs Advantage - Get a Quote Today
A: Conventional diabodies are rapidly cleared by the kidneys due to their small size (~55kDa). Our Diabody-Ig format fuses the fragment to an Fc domain, increasing the molecular weight to ~105kDa and enabling binding to the neonatal Fc Receptor (FcRn). This recycling mechanism is crucial, conferring an IgG-like half-life and ensuring sustained therapeutic concentrations in vivo.
A: Disulfide stabilization is critical for structural integrity, not just half-life. It locks the two VH-VL chains together at the Fv interface, preventing them from dissociating or engaging in unproductive chain shuffling. This engineering step guarantees high-purity, bivalent dimers, which is essential for large-scale manufacturing and predictable clinical function.
A: The affinity is primarily determined by the parental VH and VL domains. However, our rigorous engineering process is designed to ensure the stabilization steps do not compromise binding. We routinely deliver constructs with KD values in the sub-nanomolar to picomolar range, and we confirm this high affinity with comprehensive SPR kinetic analysis.
A: We consider definitive structural validation essential for a de-risked lead molecule. While these methods are advanced, they are integrated into our service as a critical quality control step, ensuring you receive a guaranteed, functional dimer. The initial investment significantly reduces the risk of failure in later, more expensive preclinical stages.
A: Yes. Our platform is perfectly suited for generating highly functional T-cell engagers. We can engineer the two binding sites to target CD3 on T cells and a specific tumor antigen, resulting in a small, rigid, bivalent, and stable molecule designed to bridge the immune and cancer cells effectively.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY
SERVICES
PRODUCTS
PLATFORMS
